GlobeNewswire: Kalytera Therapeutics, Inc. Contains the last 10 of 60 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:31:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/07/05/1879088/0/en/Kalytera-to-Hold-Annual-and-Special-Meeting-on-July-29-2019.html?f=22&fvtc=4&fvtv=31553Kalytera to Hold Annual and Special Meeting on July 29, 20192019-07-05T21:07:41Z<![CDATA[Will Seek Advance Approval for Potential Share Consolidation Will Seek Advance Approval for Potential Share Consolidation]]>https://www.globenewswire.com/news-release/2019/06/21/1872647/0/en/Kalytera-Announces-Grant-of-Stock-Options-to-Directors.html?f=22&fvtc=4&fvtv=31553Kalytera Announces Grant of Stock Options to Directors2019-06-21T21:47:19Z<![CDATA[SAN FRANCISCO and TEL AVIV, Israel, June 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has granted stock options on June 19, 2019 to the directors of the Company. The stock options have an exercise price of $0.05 per common share and expire ten years from the date of grant. One third of the options granted will vest on June 19, 2020 and the remaining options will vest in twenty-four (24) equal monthly installments commencing July 2020.]]>https://www.globenewswire.com/news-release/2019/05/14/1823874/0/en/Kalytera-Therapeutics-Inc-Announces-Second-Closing-of-Public-Offering.html?f=22&fvtc=4&fvtv=31553Kalytera Therapeutics, Inc. Announces Second Closing of Public Offering2019-05-14T14:33:29Z<![CDATA[Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.]]>https://www.globenewswire.com/news-release/2019/05/01/1813839/0/en/Kalytera-Reports-2018-Financial-Results.html?f=22&fvtc=4&fvtv=31553Kalytera Reports 2018 Financial Results2019-05-01T20:10:29Z<![CDATA[SAN FRANCISCO and TEL AVIV, Israel, May 01, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the year ended December 31 2018. (All dollars U.S. unless otherwise noted.)]]>https://www.globenewswire.com/news-release/2019/04/26/1810677/0/en/Kalytera-Therapeutics-Inc-Announces-Closing-of-Public-Offering.html?f=22&fvtc=4&fvtv=31553Kalytera Therapeutics, Inc. Announces Closing of Public Offering2019-04-26T14:16:40Z<![CDATA[Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.]]>https://www.globenewswire.com/news-release/2019/04/17/1805666/0/en/Kalytera-Therapeutics-Announces-Filing-of-Short-Form-Prospectus.html?f=22&fvtc=4&fvtv=31553Kalytera Therapeutics Announces Filing of Short Form Prospectus2019-04-17T17:02:57Z<![CDATA[/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/]]>https://www.globenewswire.com/news-release/2019/04/03/1796155/0/en/Kalytera-Therapeutics-Announces-Short-Form-Prospectus-Offering-of-Units.html?f=22&fvtc=4&fvtv=31553Kalytera Therapeutics Announces Short Form Prospectus Offering of Units2019-04-03T12:01:00Z<![CDATA[/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/]]>https://www.globenewswire.com/news-release/2019/03/07/1750300/0/en/Kalytera-Announces-Closing-of-Private-Placement-of-Convertible-Debenture-Units.html?f=22&fvtc=4&fvtv=31553Kalytera Announces Closing of Private Placement of Convertible Debenture Units2019-03-07T23:54:39Z<![CDATA[/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/]]>https://www.globenewswire.com/news-release/2019/03/05/1748082/0/en/Kalytera-Announces-Private-Placement-of-Convertible-Debenture-Units.html?f=22&fvtc=4&fvtv=31553Kalytera Announces Private Placement of Convertible Debenture Units2019-03-05T13:54:23Z<![CDATA[NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES]]>https://www.globenewswire.com/news-release/2019/02/26/1742565/0/en/Kalytera-Announces-Share-Issuance-for-January-Invoices-under-Payments-Agreements-with-Salzman-Group.html?f=22&fvtc=4&fvtv=31553Kalytera Announces Share Issuance for January Invoices under Payments Agreements with Salzman Group2019-02-26T14:26:11Z<![CDATA[SAN FRANCISCO and TEL AVIV, Israel, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 15,262,540 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under the payments agreement with The Salzman Group previously announced on December 7, 2017 (the “December 2017 Agreement”) and the additional payments agreement announced on June 15, 2018, as amended (the “June 2018 Agreement”). Under the December 2017 Agreement, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease. Under the June 2018 Agreement, which expires on March 1, 2019, The Salzman Group and its affiliates provide general and administrative support services, study set-up work for planned studies in connection with use of CBD in treatment of GVHD, services relating to clinical studies to evaluate effects of food on the pharmacokinetics of CBD and any drug-drug interactions with CBD, services relating to studies in connection with use of CBD in prevention of GVHD and other studies involving CBD, and research and development work in connection with Kalytera’s exclusive license of cannabidiol-naproxen conjugates for treatment of pain.]]>